Prestige BioPharma Limited (KRX:950210)

South Korea · Delayed Price · Currency is KRW

15,000

+230 (1.56%)

At close: Sep 9, 2025

Revenue by Product

Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2019	FY 2018
Period Ending	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018
Anti-cancer Drugs	689.73M	Log In	Log In	Log In
Anti-cancer Drugs Growth	325.85%	Log In	Log In	Log In

Revenue by Geography

Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2019	FY 2018
Period Ending	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018
Singapore	689.73M	Log In	Log In	Log In
Singapore Growth	325.85%	Log In	Log In	Log In
South Korea	-	Log In	Log In	Log In